Use of glucagon-like-peptide 1 receptor agonist in the treatment of childhood obesity.
Humans
Child
Pediatric Obesity
/ drug therapy
Glucagon-Like Peptide-1 Receptor
/ agonists
Glucagon-Like Peptides
/ therapeutic use
Adolescent
Exenatide
/ therapeutic use
Liraglutide
/ therapeutic use
Weight Loss
/ drug effects
Treatment Outcome
Anti-Obesity Agents
/ therapeutic use
Venoms
/ therapeutic use
Journal
Current opinion in pediatrics
ISSN: 1531-698X
Titre abrégé: Curr Opin Pediatr
Pays: United States
ID NLM: 9000850
Informations de publication
Date de publication:
01 Oct 2024
01 Oct 2024
Historique:
medline:
10
9
2024
pubmed:
10
9
2024
entrez:
10
9
2024
Statut:
ppublish
Résumé
Pediatric obesity is a growing epidemic. Lifestyle modifications remain central to obesity treatment, however pharmacologic options have gained traction, particularly glucagon-like peptide-1 receptor agonists (GLP-1RA). This review aims to summarize evidence on the use of GLP-1RAs in the management of pediatric obesity, physiological mechanisms of action of GLP-1RAs and their role in appetite regulation and glucose homeostasis and address the challenges and special considerations surrounding GLP-1RA use. Recent studies have highlighted the efficacy of GLP-1RAs, such as exenatide, liraglutide, and semaglutide, in promoting weight loss and improving metabolic parameters in children and adolescents. GLP-1RA's efficacy extends beyond glycemic control to include weight loss mechanisms such as delayed gastric emptying (gastroparesis), and appetite suppression. Semaglutide, the newest GLP-1RA, holds potential for substantial weight loss in adolescents and demonstrates a similar safety and efficacy as seen in adults. GLP-1RAs may offer a promising adjunct therapy for pediatric obesity, particularly in cases where lifestyle interventions alone are insufficient. However, further research is needed to elucidate long-term safety and efficacy outcomes and to address potential disparities in access to care. Overall, this review highlights the relevance and timeliness of incorporating GLP-1RAs into the comprehensive management of pediatric obesity.
Identifiants
pubmed: 39254757
doi: 10.1097/MOP.0000000000001379
pii: 00008480-202410000-00009
doi:
Substances chimiques
Glucagon-Like Peptide-1 Receptor
0
Glucagon-Like Peptides
62340-29-8
semaglutide
53AXN4NNHX
Exenatide
9P1872D4OL
Liraglutide
839I73S42A
Anti-Obesity Agents
0
Venoms
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
542-546Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Childhood Obesity Facts | Overweight & Obesity | CDC. Published July 27, 2022. https://www.cdc.gov/obesity/data/childhood.html. [Accessed 22 April 2024]
Hu K, Staiano AE. Trends in obesity prevalence among children and adolescents aged 2 to 19 years in the US from 2011 to 2020. JAMA Pediatr 2022; 176:10371039.
Kumari S, Shukla S, Acharya S. Childhood obesity: prevalence and prevention in modern society. Cureus 1984; 14:e31640.
Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics 2023; 151:e2022060640.
Berman C, Vidmar AP, Chao LC. Glucagon-like peptide-1 receptor agonists for the treatment of Type 2 diabetes in youth. TouchREV Endocrinol 2023; 19:3845.
Bensignor MO, Kelly AS, Arslanian S. Antiobesity pharmacotherapy for treatment of pediatric type 2 diabetes: review of the literature and lessons learned from adults. Front Endocrinol 2022; 13:1043650.
Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018; 27:740756.
Barrera JG, Sandoval DA, D’Alessio DA, Seeley RJ. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nat Rev Endocrinol 2011; 7:507516.
Abbott CR, Monteiro M, Small CJ, et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 2005; 1044:127131.
Morais T, Pereira SS, Andrade S, et al. GLP-1 increases circulating leptin levels in truncal vagotomized rats. Biomedicines 2023; 11:1322.
van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, nondiabetic adults. Int J Obes 20052014; 38:784793.
Krishnasamy S, Abell TL. Diabetic gastroparesis: principles and current trends in management. Diabetes Ther 2018; 9 (S1):142.
Kalas MA, Galura GM, McCallum RW. Medication-induced gastroparesis: a case report. J Investig Med High Impact Case Rep 2021; 9:23247096211051919.
Popoviciu MS, Păduraru L, Yahya G, et al. Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials. Int J Mol Sci 2023; 24:10449.
Alorfi NM, Alshehri FS. Usage of glucagon-like peptide-1 for obesity in children; updated review of Clinicaltrials.gov. J Multidiscip Heal 2023; 16:21792187.
Kelly AS, Rudser KD, Nathan BM, et al. The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial. JAMA Pediatr 2013; 167:355360.
Fox C, Clark J, Rudser K. Exenatide for weight-loss maintenance in adolescents with severe obesity: a randomized, placebo-controlled trial (vol 30, pg 1105, 2022). Obesity 2023; 31:244012440.
Liraglutide (Victoza) - PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957743/. [Accessed 26 April 2024]
Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med 2020; 382:21172128.
Malíková JK, Lebl J. GLP-1 analogues in therapy of obese adolescents. Early real-life experience with liraglutide treatment. Cesko-Slov Pediatr 2023; 78:176181.
Sykora M, Peter A, Meier D, et al. Weight loss in children and adolescents aged 10 to 17 years at a single obesity center through four different multidisciplinary treatment options including therapy with liraglutide 3 mg and bariatric surgery. Obes Facts. 2023; 16:204.
Gou H, Zhai Y, Guo J. Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials. Eur J Pediatr 2023; 182:50955108.
Qian H. Chapter 34 - Current status and trends in research and development of polypeptide drugs. In: Yu B, Li N, Fu C, editors. Privileged scaffolds in drug discovery. London: Academic Press; 2023. pp. s861-874. doi:10.1016/B978-0-443-18611-0.00024-3.
Colin IM, Gérard KM. Once-weekly 2.4 mg semaglutide for weight management in obesity: a game changer? TouchREVIEWS Endocrinol 2022; 18:3542.
Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med 2022; 387:22452257.
Weghuber D, Kelly AS, Arslanian S. Once-weekly semaglutide in adolescents with obesity. Reply. N Engl J Med 2023; 388:1146.
Tamborlane WV, Bishai R, Geller D, et al. Once-weekly exenatide in youth with Type 2 diabetes. Diabetes Care 2022; 45:18331840.
Kelly AS, Arslanian S, Hesse D, et al. Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg. Obes Silver Spring 2023; 31:21392149.
Mainieri F, La Bella S, Rinaldi M, Chiarelli F. Rare genetic forms of obesity in childhood and adolescence: a narrative review of the main treatment options with a focus on innovative pharmacological therapies. Eur J Pediatr 2024; 183:14991508.
Zaitoon H, Lubetzky R, Amir AZ, et al. Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy. Acta Diabetol 2023; 60:10991108.
Ng VWW, Gerard G, Koh JJK, et al. The role of glucagon-like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity: a systematic review. Clin Obes 2024; 14:e12642.
Shoemaker AH, Silver HJ, Buchowski M, et al. Energy balance in hypothalamic obesity in response to treatment with a once-weekly GLP-1 receptor agonist. Int J Obes 2022; 46:623629.
Baden CS, Andersen JT, Christensen MB, Gade C. Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: a scoping review. Adverse Drug React Bull 2023; 339:13151318.
Kelly AS. Current and future pharmacotherapies for obesity in children and adolescents. Nat Rev Endocrinol 2023; 19:534541.
215256s000lbl.pdf. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf. [Accessed 22 April 2024]
Bomberg EM, Palzer EF, Rudser KD, et al. Antiobesity medication prescriptions by race/ethnicity and use of an interpreter in a pediatric weight management clinic. Ther Adv Endocrinol Metab 2022; 13:20420188221090009.
Ludwig DS, Holst JJ. Childhood obesity at the crossroads of science and social justice. JAMA 2023; 329:19091910.
Mital S, Nguyen HV. Cost-effectiveness of antiobesity drugs for adolescents with severe obesity. JAMA Netw Open 2023; 6:e2336400.